Davis Kim 4

What Happened Davis Kim, Chief Legal Officer of Zura Bio Ltd (ZURA), received an award of rights to 425,700 derivative shares (reported as an option award) on April 1, 2026. The Form 4 shows an acquisition code A with a reported price of $0.00, indicating a grant rather than an open‑market purchase or sale. This is a grant of equity compensation — not an immediate sale — and does not by itself represent a cash transaction.

Key Details

• Transaction date: 2026-04-01; filing date: 2026-04-02 (timely filed).
• Transaction type/code: Award/Grant (derivative) — 425,700 shares; reported price $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Notable footnote: Vesting schedule — 1/4 of the shares vest on April 1, 2027; thereafter 1/12 of the remaining shares vest in equal quarterly installments, subject to continuous service.
• No tax withholding, 10b5-1 plan, or late‑filing indication noted in the supplied information.

Context This filing reports an option/equity award subject to a time‑based vesting schedule; such grants are standard executive compensation and do not indicate immediate market activity (no cashless exercise or sale reported). Retail investors should view this as a granted long‑term incentive for the officer rather than a signal of buying or selling stock.